Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis-Reference-Cited by-同舟云学术

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Published:2020-11 Issue:11 Volume:31 Page:1536-1544
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Papadimitrakopoulou V.A.,Mok T.S.,Han J.-Y.,Ahn M.-J.,Delmonte A.,Ramalingam S.S.,Kim S.W.,Shepherd F.A.,Laskin J.,He Y.,Akamatsu H.,Theelen W.S.M.E.,Su W.-C.,John T.,Sebastian M.,Mann H.,Miranda M.,Laus G.,Rukazenkov Y.,Wu Y.-L.

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference27 articles.

1. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update;Hanna;J Clin Oncol,2017

2. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2019

3. Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis;Wang;BMC Cancer,2018

4. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer;John;Lung Cancer,2018

5. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov,2014

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial;Lung Cancer;2024-09

2. Immunotherapy Improves the Survival of Stage 4 Non–Small Cell Lung Cancer Patients at the US Population Level: The Real‐World Evidence;The Clinical Respiratory Journal;2024-09

3. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development;Cancer Treatment Reviews;2024-09

4. Prognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study;Drugs - Real World Outcomes;2024-08-29

5. Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer;British Journal of Clinical Pharmacology;2024-08-19